Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05819866 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

Study acronym: CALYX
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Study sites: 13 to 11
    v15
  2. Site contacts updated at 1 of 13 sitesv14
  3. Site contacts updated at 1 of 13 sitesv13
  4. Study sites: 12 to 13v12
  5. Site contacts updated at 1 of 12 sitesv11
Show 9 earlier versionsHide 9 earlier versions
  1. Study sites: 8 to 12v10
  2. Site details revised at 3 of 8 sitesv9
  3. Site details revised at 3 of 8 sitesv8
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2023 to Jul 12, 2023
    • Site details revised at 8 of 8 sites
    v7
  5. Study sites revised (8)v6
  6. Study sites: 7 to 8v5
  7. Study sites: 6 to 7v4
  8. Study sites: 7 to 6
    • Start date: Jun 2023 to Jul 2023
    v3
  9. Start date: May 2023 to Jun 2023
    • Study sites revised (7)
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Trial Details
NCT Number NCT05819866
Lead Sponsor Minoryx Therapeutics, S.L.
Conditions
(from sponsor)		 Cerebral Adrenoleukodystrophy (cALD)
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov